R Somayaji1, C H Goss2,3. 1. Departments of Medicine and Microbiology, Immunology & Infectious Disease, University of Calgary, Calgary, Alberta CA. 2. Departments of Medicine and Pediatrics, University of Washington School of Medicine, Seattle WA. 3. CFF Therapeutics Development Network Coordinating Center, Seattle Children's Research Institute, Seattle WA.
Abstract
PURPOSE OF REVIEW: a)We conducted a review of the current evidence relating to antibiotic duration in the short and long-term management of non-cystic fibrosis bronchiectasis. RECENT FINDINGS: b)In non-cystic fibrosis pulmonary exacerbations, evidence is primarily based on expert consensus and recent guidelines recommend antibiotic durations of approximately 14 days. Chronic antibiotics (oral or inhaled) are recommended in patients with frequent exacerbations or with chronic Pseudomonas aeruginosa airways infection. Macrolides are the best studied therapies for long-term use with evidence for effect limited to a 12 month duration. Encouragingly, there are increased efforts to develop registries and conduct larger population level studies to improve patient care. SUMMARY: c)There is a paucity of evidence for optimal antibiotic strategies in exacerbations and chronic maintenance in persons with non-cystic fibrosis bronchiectasis. Rationally designed studies which utilize a registry and population-based approach will be critical to build evidence-based strategies to optimize management of non-cystic fibrosis bronchiectasis.
PURPOSE OF REVIEW: a)We conducted a review of the current evidence relating to antibiotic duration in the short and long-term management of non-cystic fibrosis bronchiectasis. RECENT FINDINGS: b)In non-cystic fibrosis pulmonary exacerbations, evidence is primarily based on expert consensus and recent guidelines recommend antibiotic durations of approximately 14 days. Chronic antibiotics (oral or inhaled) are recommended in patients with frequent exacerbations or with chronic Pseudomonas aeruginosa airways infection. Macrolides are the best studied therapies for long-term use with evidence for effect limited to a 12 month duration. Encouragingly, there are increased efforts to develop registries and conduct larger population level studies to improve patient care. SUMMARY: c)There is a paucity of evidence for optimal antibiotic strategies in exacerbations and chronic maintenance in persons with non-cystic fibrosis bronchiectasis. Rationally designed studies which utilize a registry and population-based approach will be critical to build evidence-based strategies to optimize management of non-cystic fibrosis bronchiectasis.
Authors: J Angrill; C Agustí; R de Celis; A Rañó; J Gonzalez; T Solé; A Xaubet; R Rodriguez-Roisin; A Torres Journal: Thorax Date: 2002-01 Impact factor: 9.139
Authors: Laura White; Ghazi Mirrani; Mark Grover; Judith Rollason; Adam Malin; Jay Suntharalingam Journal: Respir Med Date: 2011-12-26 Impact factor: 3.415
Authors: Anthony De Soyza; Audrey Perry; Amanda J Hall; Syba S Sunny; Kathy E Walton; Nazim Mustafa; Jane Turton; Dervla T Kenna; Craig Winstanley Journal: Eur Respir J Date: 2013-10-31 Impact factor: 16.671
Authors: Jonathan D Cogen; Kathryn B Whitlock; Ronald L Gibson; Lucas R Hoffman; Donald R VanDevanter Journal: J Cyst Fibros Date: 2019-05-28 Impact factor: 5.482
Authors: Michael M Tunney; Gisli G Einarsson; Lan Wei; Maire Drain; Erich R Klem; Chris Cardwell; Madeleine Ennis; Richard C Boucher; Matthew C Wolfgang; J Stuart Elborn Journal: Am J Respir Crit Care Med Date: 2013-05-15 Impact factor: 21.405
Authors: James D Chalmers; Maeve P Smith; Brian J McHugh; Cathy Doherty; John R Govan; Adam T Hill Journal: Am J Respir Crit Care Med Date: 2012-06-28 Impact factor: 21.405
Authors: Khin Hnin; Chau Nguyen; Kristin V Carson; David J Evans; Michael Greenstone; Brian J Smith Journal: Cochrane Database Syst Rev Date: 2015-08-13
Authors: Mark J Hoegger; Anthony J Fischer; James D McMenimen; Lynda S Ostedgaard; Alex J Tucker; Maged A Awadalla; Thomas O Moninger; Andrew S Michalski; Eric A Hoffman; Joseph Zabner; David A Stoltz; Michael J Welsh Journal: Science Date: 2014-08-15 Impact factor: 47.728